Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Boothbay Fund Management LLC

Boothbay Fund Management LLC cut its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 29.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 106,309 shares of the medical technology company's stock after selling 44,867 shares during the period. Boothbay Fund Management LLC owned about 0.07% of Alphatec worth $976,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Barclays PLC raised its stake in Alphatec by 362.3% during the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock valued at $948,000 after purchasing an additional 133,653 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Alphatec by 299.3% in the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock worth $343,000 after buying an additional 48,308 shares in the last quarter. Congress Asset Management Co. boosted its position in shares of Alphatec by 235.4% during the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock worth $3,993,000 after acquiring an additional 305,296 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Alphatec by 1.3% during the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock worth $1,277,000 after acquiring an additional 1,746 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Alphatec by 20.0% during the fourth quarter. Russell Investments Group Ltd. now owns 199,886 shares of the medical technology company's stock valued at $1,835,000 after acquiring an additional 33,362 shares in the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Alphatec

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the sale, the chief executive officer now directly owns 5,857,603 shares of the company's stock, valued at $62,324,895.92. This trade represents a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Scott Lish sold 27,453 shares of the firm's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 185,857 shares of company stock worth $2,105,682 in the last 90 days. 22.80% of the stock is owned by insiders.

Alphatec Trading Up 0.1 %

Shares of Alphatec stock traded up $0.02 during mid-day trading on Monday, hitting $12.02. The stock had a trading volume of 564,700 shares, compared to its average volume of 2,069,121. The firm has a 50-day moving average of $10.46 and a two-hundred day moving average of $9.92. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a market cap of $1.76 billion, a P/E ratio of -9.39 and a beta of 1.20. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The business had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Alphatec's quarterly revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.34) earnings per share. Sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATEC has been the subject of several research reports. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Barclays raised their price target on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a report on Friday. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.